SEC Form 4 · accession 0000891293-15-000021
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Jun 4, 2015
Accepted (ET)
Jun 5, 2015 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 4, 2015 | S | 2,500 | $2.05 | D | 699,240 | D | |
| Common Stock | Jun 4, 2015 | S | 1,000 | $2.055 | D | 698,240 | D | |
| Common Stock | Jun 4, 2015 | S | 2,400 | $2.06 | D | 695,840 | D | |
| Common Stock | Jun 4, 2015 | S | 100 | $2.065 | D | 695,740 | D | |
| Common Stock | Jun 4, 2015 | S | 3,700 | $2.07 | D | 692,040 | D | |
| Common Stock | Jun 4, 2015 | S | 200 | $2.075 | D | 691,840 | D | |
| Common Stock | Jun 4, 2015 | S | 100 | $2.08 | D | 691,740 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.